In this article, we will be taking a look at the 5 Best Innovative Healthcare Stocks to Buy Now. If you wish to see the full list, visit 10 Best Innovative Healthcare Stocks to Buy Now.
5. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Number of Hedge Fund Holders: 60
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best healthcare stocks on our list.
TheFly reported on June 25 that H.C. Wainwright increased its price target on IONS to $130 from $125 while maintaining a Buy rating on the shares. The revision followed the U.S. Food and Drug Administration’s approval of Tryngolza.
In other news, on July 6, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced the completion of enrollment in Cohort 1 of the global Phase 3 REVEAL study evaluating obudanersen (ION582), an investigational RNA-targeted therapy for individuals with Angelman syndrome. The pivotal cohort enrolled 136 participants between the ages of 2 and under 18 with genetically confirmed UBE3A deletion or mutation. The company expects enrollment in the adult cohort, which includes participants aged 18 to 50, to conclude in the third quarter of 2026. Topline results from the REVEAL study are anticipated in the second half of 2027. Ionis stated that the trial was designed with input from the Angelman syndrome community to evaluate the therapy across a broad patient population.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a biotechnology leader in RNA-targeted medicines, pioneering antisense oligonucleotide (ASO) therapies. The company develops treatments for rare, neurological, and cardiometabolic diseases by using ASO, siRNA, and gene-editing technologies to regulate disease-causing proteins and improve drug delivery.
4. Agilent Technologies, Inc. (NYSE:A)
Number of Hedge Fund Holders: 63
Agilent Technologies, Inc. (NYSE:A) is one of the best healthcare stocks on our list.
TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar increased the firm’s price target on A to $148 from $144 while maintaining an Outperform rating on the shares. The revised target came as part of the firm’s second-quarter outlook covering the MedTech, Life Sciences Tools, and Diagnostics sectors. Evercore ISI noted that industry trends remain supported by generally stable procedure volumes and capital spending activity, according to a research note shared with investors.
Separately, earlier this month on July 1, Agilent Technologies, Inc. (NYSE:A) announced the introduction of Agilent xCELLigence RTCA eSight AI, an artificial intelligence-enabled software module designed to improve label-free imaging analysis. The new solution reduces the need for manual cell segmentation and parameter adjustments while helping researchers achieve more consistent analytical outcomes. The software expands the capabilities of the Agilent xCELLigence RTCA eSight platform by integrating AI-based imaging analysis with its existing dual-readout technology, allowing users to collect both imaging and impedance data from identical cells within a single experiment. The upgraded system is designed to provide biopharmaceutical researchers with a more comprehensive understanding of cellular activity while improving workflow efficiency and minimizing variation caused by different users or experimental conditions.
Agilent Technologies, Inc. (NYSE:A) is a global leader in life sciences, diagnostics, and applied chemical markets, providing laboratory instruments, software, and solutions. Its innovations support cancer diagnostics, biotherapeutics, and genomics research, enabling more precise and personalized healthcare.
3. United Therapeutics Corporation (NASDAQ:UTHR)
Number of Hedge Fund Holders: 64
United Therapeutics Corporation (NASDAQ:UTHR) is one of the best healthcare stocks on our list.
TheFly reported on June 29 that Leerink Partners characterized the FDA’s premarket approval of LungFX for UTHR as a positive development for the company and the broader transplantation sector. The firm stated that the approval marks another regulatory advancement supporting UTHR’ long-term organ manufacturing strategy. According to the analyst, the milestone further reinforces the company’s potential position in the development of centralized ex vivo lung perfusion technologies. Leerink maintains an Outperform rating on United Therapeutics shares.
In other news, on July 2, United Therapeutics Corporation (NASDAQ:UTHR) announced the acquisition of Thymmune Therapeutics, a privately held biotechnology company focused on developing regenerative thymic cell therapies for potential applications in transplant tolerance, immune disorders, and autoimmune conditions. Thymmune’s technology uses human-induced pluripotent stem cells to create thymic cells that may help restore functional T-cell activity after integration into the body. The company’s lead program, THY-100, is being developed for congenital athymia, a rare and severe disorder caused by the absence of a functioning thymus. United Therapeutics completed the acquisition for $140 million in cash, subject to adjustments, along with potential additional earn-out payments of up to $160 million tied to clinical and regulatory milestones through 2031.
United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on treating life-threatening diseases, including pulmonary arterial hypertension (PAH), while addressing the global organ shortage. Its portfolio includes FDA-approved PAH therapies such as Tyvaso, Remodulin, and Orenitram, along with innovations in xenotransplantation, 3D bioprinting, cellular regeneration, and ex vivo lung perfusion to advance organ transplantation.
2. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Number of Hedge Fund Holders: 72
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks on our list.
TheFly reported on July 6 that HSBC reduced its price target on REGN to $800 from $990 while maintaining a Buy rating on the shares. The adjustment was included in a broader healthcare sector update, where HSBC reviewed the potential for relative sector strength in the second half of the year. The firm highlighted therapeutics as offering attractive risk-adjusted opportunities, identified life sciences tools as a potential beneficiary of a cyclical recovery, and noted that medical technology companies appear undervalued.
Earlier on June 22, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the U.S. Food and Drug Administration and European Medicines Agency accepted regulatory submissions for cemdisiran as a potential treatment for adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies. The FDA granted the application Priority Review, with a target decision expected in November 2026 following the use of a priority review voucher. A European Commission decision is anticipated during the second half of 2027. The regulatory filings are supported by results from the Phase 3 NIMBLE study, which evaluated subcutaneous dosing of cemdisiran every 12 weeks in adults with symptomatic gMG, including patients who may also receive standard immunosuppressive therapies.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a leading biopharmaceutical company developing life-changing medicines for serious diseases. It leverages advanced genetic research, data analytics, and proprietary platforms like VelociSuite, Regeneron Genetics Center, and genetic medicine technologies to accelerate drug discovery and create targeted therapies.
1. Abbott Laboratories (NYSE:ABT)
Number of Hedge Fund Holders: 73
Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks on our list.
TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares. The updated target was included in the firm’s second-quarter outlook for the MedTech, Life Sciences Tools, and Diagnostics industries. Evercore ISI noted that sector conditions remain supported by relatively healthy procedure volumes and capital spending trends, according to a research note shared with investors.
Earlier on July 1, Tandem Diabetes Care announced that its t: slim X2 insulin pump featuring Control-IQ+ automated insulin delivery technology is now compatible with Abbott Laboratories (NYSE:ABT)’s FreeStyle Libre 3 Plus continuous glucose monitoring sensor across five countries. The expansion provides users in the United Kingdom, Switzerland, Sweden, Finland, and Italy with additional CGM options while using Tandem’s automated insulin delivery system. The company expects to broaden availability to more European markets, including Belgium, the Netherlands, and Germany, during 2026. Tandem stated that expanding sensor compatibility supports greater flexibility for people using automated insulin delivery technology and enhances choice within its diabetes management ecosystem.
Abbott Laboratories (NYSE:ABT) is a global healthcare innovator advancing medical devices, diagnostics, nutrition, and pharmaceuticals. Its key innovations include FreeStyle Libre continuous glucose monitoring, AVEIR leadless pacemakers, and digital health technologies, while expanding access to advanced healthcare solutions worldwide.
While we acknowledge the potential of ABT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: Billionaire Cliff Asness’ Top 10 Healthcare Stock Picks and 10 Best Stocks to Buy Now for Good Returns.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.
